



## Accelero reports financial results for its fiscal year 2020

2021 forecast sees turnover >30% up with approx. 12% sales revenues

Berlin, 14 April 2021

Accelero Bioanalytics GmbH ("Accelero") announced key figures for the fiscal year 2020 in Germany's Federal Gazette.

In the light of the global financial crisis triggered by the SARS-CoV-2 pandemic, turnover nevertheless went up by 9% (Previous year 2019: 72%). Sales revenues remain constant with 3% (Previous year 2019: 4%). Approx. 70% of the years' turnover is created by clients outside Germany.

Accelero currently experiences an extraordinary service order increase. 2021 first quarter results went up by 89% in comparison to the same period last year (Previous year 2020: 0%). Q1 2021 sales revenues accumulated to 14.7%.

The forecast has therefore been raised for the current year 2021. Accelero expects to continue creating high turnover throughout the year, resulting in an overall 30% turnover increase with approx. 12% sales revenues by end of 2021. An outstanding feature is a contractual agreement covering the GLP-compliant development of a virus-based next generation COVID 19 vaccine.

For additional information on Accelero's services, please feel free to use our website contact form, or send us an email to [service\(at\)accelero-bioanalytics.com](mailto:service(at)accelero-bioanalytics.com). The Accelero team will be happy to assist you.

Accelero Bioanalytics GmbH  
Center for Biotechnology and Environment  
Volmerstrasse 9A  
12489 Berlin  
GERMANY

Primary Contact:  
Christian Lange, Founder & Managing Director  
Telephone +49 30 610 910 300

qPCR  
Biodistribution  
ELISA  
EliSpot / FluoroSpot  
Flow cytometry  
Multiplex immunoassays  
Multiplex miRNA assays  
Cell culture  
Microbiology  
GLP trainings & seminars

Follow us on



Read [binding-assay.com](http://binding-assay.com) for blog and case studies.

